Pharmaceutical Industry Reports Plasmid DNA Manufacturing | Page 2

REPORT DESCRIPTION
Plasmid DNA Manufacturing Market – Overview
Increasing number of patients opting for gene therapy is a major factor driving growth of the plasmid DNA
manufacturing market. Gene therapy is a leading field in medical science, which promises new treatment
development for patients suffering from various diseases.
Several clinical trials are being conducted on viral vectors and plasmid DNA manufacturing that are focused on
the potential of gene therapy. Increasing investments in drug development and commercialization of these
therapies in order to meet significant medical needs are factors driving the market growth. These genetic markers
are associated with complex diseases, therefore it is important to study about the genetic information and its
clinical application in designing clinical trials and gene therapy product manufacturing.
According to a data published by the Journal of Gene Medicine: March 2018, till November 2017, an estimated
2,600 gene therapy clinical trials were ongoing, have been completed, or have been approved in 36 countries.
Countries where the trials were conducted include the U.S., the U.K., Australia, Canada, China, France, Germany,
Japan, Switzerland, the Netherlands, and others.